Truist analyst Joon Lee raised the firm’s price target on PTC Therapeutics (PTCT) to $86 from $80 and keeps a Buy rating on the shares. PTC announced Sephience was approved for phenylketonuria with the broadest label possible, from 1 month of age and older, and recent checks imply pent-up demand, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Buy Rating Driven by Sephience Approval and Market Strategy
- PTC Therapeutics price target raised to $78 from $74 at Wells Fargo
- Positive Outlook for PTC Therapeutics: Buy Rating Affirmed Following Sephience Approval and Strategic Launch
- PTC Therapeutics price target raised to $80 from $71 at UBS
- Positive Outlook for PTC Therapeutics’ Sephience: Strong Market Potential and Revenue Prospects